Kelleher Financial Advisors Sells 1,463 Shares of Eli Lilly and Company $LLY

Kelleher Financial Advisors trimmed its position in Eli Lilly and Company (NYSE:LLY) by 58.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 1,035 shares of the company’s stock after selling 1,463 shares during the period. Kelleher Financial Advisors’ holdings in Eli Lilly and Company were worth $1,198,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Coastal Bridge Advisors LLC bought a new stake in Eli Lilly and Company in the second quarter worth $2,959,000. Birinyi Associates Inc. raised its holdings in shares of Eli Lilly and Company by 32.6% during the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after purchasing an additional 359 shares during the last quarter. Mosaic Family Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after purchasing an additional 1,430 shares during the last quarter. Heritage Investors Management Corp lifted its position in Eli Lilly and Company by 6.5% during the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock valued at $13,624,000 after purchasing an additional 718 shares during the period. Finally, Moran Wealth Management LLC lifted its position in Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after purchasing an additional 9,638 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.6%

Shares of LLY opened at $1,418.14 on Thursday. The stock has a market capitalization of $1.33 trillion, a PE ratio of 46.03, a P/E/G ratio of 1.76 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,449.68. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company’s fifty day moving average is $1,207.75 and its 200 day moving average is $1,097.85.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm posted $7.02 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Analyst Upgrades and Downgrades

LLY has been the topic of several research reports. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Argus increased their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. BMO Capital Markets restated an “outperform” rating and set a $1,650.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,500 shares of company stock valued at $22,970,770 in the last quarter. 0.14% of the stock is owned by insiders.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A report says Cantor Fitzgerald raised its price target to $1,600 from $1,440 and kept an “overweight” rating, adding to analyst optimism. Cantor Fitzgerald price-target update
• Positive Sentiment: Lilly advanced a next-generation obesity treatment into a Phase 3 study. Further progress could strengthen its pipeline beyond current weight-loss drugs, although the report provides limited trial details. Lilly advances Phase 3 obesity study
• Positive Sentiment: ETFs reportedly bought about $105 million of LLY shares on Nov. 2, suggesting institutional fund demand that may support the stock. ETF purchases of Lilly shares
• Positive Sentiment: In a challenge brought by Lilly, the National Advertising Division recommended that Good Life Meds stop or revise certain claims about compounded tirzepatide products. The recommendation could help Lilly contest marketing by compounded-drug competitors. Advertising claims recommendation
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale is notable, though the planned nature makes it less clear as a signal about the company’s outlook. Insider sale report
• Negative Sentiment: Recent commentary questions the quality and durability of Lilly’s growth, citing possible one-off revenue benefits and lower realized prices. With expectations and valuation elevated, any deceleration could pressure the shares. Revenue growth quality concerns

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.